Influence of sorafenib and transcatheter arterial chemoembolization (TACE) on pancreatic volume in patients with advanced hepatocarcinoma.

Congress:

ECR 2020

Poster Number:

C-04273

Type:

Scientific Exhibit

Keywords:

Oncologic Imaging, Interventional vascular, Oncology, Pancreas, CT, Segmentation, Drugs / Reactions, Toxicity, Retrospective, Cross-sectional study, Performed at one institution

Authors:

E. Belmonte Castán, A. Darnell, J. Rimola, V. Sapena, M. Reig, C. Ayuso; Barcelona/ES

DOI:

10.26044/ecr2020/C-04273

DOI-Link:

https://dx.doi.org/10.26044/ecr2020/C-04273

Conclusion

Sorafenib administration was mainly associated to a reduction of pancreatic volume during follow-up. Pancreatic volume remains stable in the TACE group.

The suspected mechanism in reduction of pancreatric volume in patients under sorafenib is the anti-angiogenic effect of the inhibited vacular endothelial growth factor causing a disturbance of microvasculation. Although the incidence of acute pancreatitis after TACE has been reported, we have not appreciated changes in pancreatic volumetry in our group.

Radiologists must be awared of changes in pancreatic volumetry to asses their clinical side effects, in patients treated with sorafenib.